Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMD NASDAQ:IRMD NYSE:NVRO NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$14.29-2.5%$14.27$13.14▼$19.85$902.96M1.931.28 million shs765,158 shsIRMDiRadimed$69.70-1.8%$60.90$43.17▼$73.47$886.60M0.9444,503 shs22,090 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.34$224.32M0.81818,428 shs753,602 shsTNDMTandem Diabetes Care$10.86-2.5%$16.99$9.98▼$47.60$733.46M1.461.71 million shs995,566 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode+3.02%+4.79%-0.61%-0.41%-8.72%IRMDiRadimed-2.74%+0.97%+22.27%+31.82%+61.44%NVRONevro0.00%0.00%0.00%0.00%+6.29%TNDMTandem Diabetes Care+0.27%-22.65%-29.33%-50.97%-73.25%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINMDInMode2.4418 of 5 stars2.14.00.00.02.31.71.9IRMDiRadimed4.3058 of 5 stars1.53.01.74.42.04.21.9NVRONevroN/AN/AN/AN/AN/AN/AN/AN/ATNDMTandem Diabetes Care4.2593 of 5 stars4.11.00.04.92.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMDInMode 2.13Hold$18.0426.30% UpsideIRMDiRadimed 3.00Buy$72.003.30% UpsideNVRONevro 2.00Hold$5.36-8.29% DownsideTNDMTandem Diabetes Care 2.20Hold$22.67108.81% UpsideCurrent Analyst Ratings BreakdownLatest NVRO, INMD, IRMD, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$53.00 ➝ $51.008/7/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$59.00 ➝ $24.008/7/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$30.00 ➝ $14.008/7/2025TNDMTandem Diabetes CareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$20.00 ➝ $17.008/7/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $13.008/7/2025TNDMTandem Diabetes CareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $25.007/30/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold7/30/2025INMDInModeBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $21.007/11/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$15.007/9/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Sell$24.00 ➝ $14.00(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMDInMode$394.82M2.29$1.83 per share7.80$9.94 per share1.44IRMDiRadimed$73.24M12.11$1.51 per share46.14$7.41 per share9.41NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72TNDMTandem Diabetes Care$1.00B0.73N/AN/A$1.97 per share5.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMDInMode$181.27M$2.475.787.85N/A44.50%18.38%16.35%10/29/2025 (Estimated)IRMDiRadimed$19.23M$1.6243.0334.85N/A26.61%23.30%20.62%10/30/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%N/ATNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%N/ALatest NVRO, INMD, IRMD, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMDInModeN/AN/AN/AN/AN/AIRMDiRadimed$0.680.98%N/A41.98%1 YearsNVRONevroN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ALatest NVRO, INMD, IRMD, and TNDM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/31/2025IRMDiRadimedquarterly$0.171.13%8/18/20258/18/20258/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMDInModeN/A9.608.58IRMDiRadimedN/A8.787.51NVRONevro0.675.023.76TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMDInMode68.04%IRMDiRadimed92.34%NVRONevro95.52%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINMDInMode6.92%IRMDiRadimed36.80%NVRONevro3.20%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMDInMode48063.21 million58.84 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableNVRO, INMD, IRMD, and TNDM HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money -- Contact Law Offices of Howard G. ...2 hours ago | gurufocus.comTandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation3 hours ago | businesswire.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from AnalystsAugust 14 at 2:38 AM | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Cut to "Hold" at Lake Street CapitalAugust 14 at 2:03 AM | americanbankingnews.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzAugust 13 at 8:44 PM | businesswire.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up Following Insider Buying ActivityAugust 13 at 10:52 AM | marketbeat.com5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings CallAugust 13 at 7:30 AM | finance.yahoo.comTandem Diabetes Care: Strategic Growth Potential and Market Expansion Drive Buy RatingAugust 13 at 7:14 AM | tipranks.comTandem Diabetes Care Gains FDA Clearance for SteadiSetAugust 13 at 2:30 AM | theglobeandmail.comTandem Diabetes Care (TNDM) was downgraded to a Hold Rating at Piper SandlerAugust 13 at 2:30 AM | theglobeandmail.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Insider Buying ActivityAugust 13 at 2:08 AM | americanbankingnews.comCitigroup Upgrades Tandem Diabetes Care (TNDM)August 12 at 9:28 PM | msn.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) CEO Acquires $102,300.00 in StockAugust 12 at 8:06 PM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) CFO Acquires $149,410.80 in StockAugust 12 at 8:06 PM | marketbeat.comTandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To KnowAugust 12 at 4:28 PM | msn.comTandem Diabetes upgraded at Citi on risk-reward setupAugust 12 at 4:28 PM | msn.comTandem Diabetes Care (NASDAQ:TNDM) Given "Hold" Rating at Lake Street CapitalAugust 12 at 12:33 PM | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.6% After Analyst DowngradeAugust 12 at 10:32 AM | marketbeat.comCitigroup Upgrades Tandem Diabetes Care (TNDM) Rating to Neutral | TNDM Stock NewsAugust 12 at 7:07 AM | gurufocus.comTNDM Q2 Deep Dive: Margin Pressures and Strategic Shifts Offset Sales GrowthAugust 12 at 6:33 AM | finance.yahoo.comConnor Clark & Lunn Investment Management Ltd. Has $12.36 Million Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)August 12 at 5:18 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVRO, INMD, IRMD, and TNDM Company DescriptionsInMode NASDAQ:INMD$14.28 -0.37 (-2.49%) As of 02:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.iRadimed NASDAQ:IRMD$69.70 -1.30 (-1.83%) As of 02:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Nevro NYSE:NVRONevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Tandem Diabetes Care NASDAQ:TNDM$10.86 -0.28 (-2.47%) As of 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cisco Systems: The Only AI Stock Income Investors Need to Own Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests 5 Stocks Insiders Are Selling That Analysts Say Buy CoreWeave Pulls Back Into a Screaming Buy Amazon’s Bears Have Raised the White Flag—Get Excited Rocket Lab Scores Analyst Upgrades, Finalizes Geost Takeover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access